PubMed:11705854 JSONTXT

{"project":"FSU-PRGE","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"protein"},{"id":"T2","span":{"begin":40,"end":43},"obj":"protein"},{"id":"T3","span":{"begin":161,"end":180},"obj":"protein"},{"id":"T4","span":{"begin":291,"end":311},"obj":"protein"},{"id":"T5","span":{"begin":313,"end":316},"obj":"protein"},{"id":"T6","span":{"begin":526,"end":529},"obj":"protein"},{"id":"T7","span":{"begin":640,"end":643},"obj":"protein"},{"id":"T8","span":{"begin":678,"end":682},"obj":"protein"},{"id":"T9","span":{"begin":849,"end":852},"obj":"protein"},{"id":"T10","span":{"begin":1150,"end":1153},"obj":"protein"},{"id":"T11","span":{"begin":1219,"end":1222},"obj":"protein"},{"id":"T12","span":{"begin":1568,"end":1571},"obj":"protein"}],"text":"Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy.\nPURPOSE: Carbonic anhydrases are proteins involved in the catalytic hydration of carbon dioxide to carbonic acid. Recent studies show that carbonic anhydrase 9 (CA9) is up-regulated by hypoxia and that its immunohistochemical tissue distribution follows the distribution of the radiosensitizer pimonidazole (C. C. Wykoff et al., Cancer Res. 60: 7075-7083, 2001). Therefore, CA9 expression may show hypoxia levels of clinical importance.\nEXPERIMENTAL DESIGN: We assessed the expression of CA9 and the microvessel density (MVD; CD31-positive) in 75 locally advanced squamous cell head and neck cancers treated with concurrent chemoradiotherapy with carboplatin.\nRESULTS: Strong membrane/cytoplasmic CA9 expression, noted in 20/75 (26.6%) tumors, mainly occurred in tumors with very poor vascularization (expression in 63% versus 14%; P \u003c 0.0001), was located around areas of focal necrosis, and was related to poor complete response rate (40% versus 70%; P = 0.02). These observations suggested that CA9 might be a marker of clinically important hypoxia. Combining the CA9 staining and the tumor angiogenicity (MVD), we identified three groups of patients: (a) hypoxic tumors; (b) euoxic highly angiogenic tumors; and (c) euoxic non-highly angiogenic tumors. Groups (a) and (b) had a very poor local relapse-free survival (P \u003c 0.0001).\nCONCLUSIONS: Stratification of patients undergoing radical radiotherapy using the CA9/MVD model may be useful for the individualization of therapeutic strategies combining antiangiogenesis and hypoxia targeting with radiotherapy."}

{"project":"PIR-corpus2","denotations":[{"id":"T1","span":{"begin":0,"end":44},"obj":"protein"},{"id":"T2","span":{"begin":161,"end":180},"obj":"protein"},{"id":"T3","span":{"begin":291,"end":317},"obj":"protein"},{"id":"T4","span":{"begin":526,"end":529},"obj":"protein"},{"id":"T5","span":{"begin":640,"end":643},"obj":"protein"},{"id":"T6","span":{"begin":849,"end":852},"obj":"protein"},{"id":"T7","span":{"begin":1150,"end":1153},"obj":"protein"},{"id":"T8","span":{"begin":1219,"end":1222},"obj":"protein"},{"id":"T9","span":{"begin":1568,"end":1571},"obj":"protein"}],"text":"Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy.\nPURPOSE: Carbonic anhydrases are proteins involved in the catalytic hydration of carbon dioxide to carbonic acid. Recent studies show that carbonic anhydrase 9 (CA9) is up-regulated by hypoxia and that its immunohistochemical tissue distribution follows the distribution of the radiosensitizer pimonidazole (C. C. Wykoff et al., Cancer Res. 60: 7075-7083, 2001). Therefore, CA9 expression may show hypoxia levels of clinical importance.\nEXPERIMENTAL DESIGN: We assessed the expression of CA9 and the microvessel density (MVD; CD31-positive) in 75 locally advanced squamous cell head and neck cancers treated with concurrent chemoradiotherapy with carboplatin.\nRESULTS: Strong membrane/cytoplasmic CA9 expression, noted in 20/75 (26.6%) tumors, mainly occurred in tumors with very poor vascularization (expression in 63% versus 14%; P \u003c 0.0001), was located around areas of focal necrosis, and was related to poor complete response rate (40% versus 70%; P = 0.02). These observations suggested that CA9 might be a marker of clinically important hypoxia. Combining the CA9 staining and the tumor angiogenicity (MVD), we identified three groups of patients: (a) hypoxic tumors; (b) euoxic highly angiogenic tumors; and (c) euoxic non-highly angiogenic tumors. Groups (a) and (b) had a very poor local relapse-free survival (P \u003c 0.0001).\nCONCLUSIONS: Stratification of patients undergoing radical radiotherapy using the CA9/MVD model may be useful for the individualization of therapeutic strategies combining antiangiogenesis and hypoxia targeting with radiotherapy."}

{"project":"PIR-corpus1","denotations":[{"id":"T1","span":{"begin":18,"end":38},"obj":"protein"},{"id":"T2","span":{"begin":40,"end":43},"obj":"acronym"},{"id":"T3","span":{"begin":161,"end":180},"obj":"protein"},{"id":"T4","span":{"begin":185,"end":193},"obj":"protein"},{"id":"T5","span":{"begin":291,"end":311},"obj":"protein"},{"id":"T6","span":{"begin":313,"end":316},"obj":"acronym"},{"id":"T7","span":{"begin":526,"end":529},"obj":"protein"},{"id":"T8","span":{"begin":640,"end":643},"obj":"protein"},{"id":"T9","span":{"begin":849,"end":852},"obj":"protein"},{"id":"T10","span":{"begin":1150,"end":1153},"obj":"protein"},{"id":"T11","span":{"begin":1219,"end":1222},"obj":"protein"}],"text":"Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy.\nPURPOSE: Carbonic anhydrases are proteins involved in the catalytic hydration of carbon dioxide to carbonic acid. Recent studies show that carbonic anhydrase 9 (CA9) is up-regulated by hypoxia and that its immunohistochemical tissue distribution follows the distribution of the radiosensitizer pimonidazole (C. C. Wykoff et al., Cancer Res. 60: 7075-7083, 2001). Therefore, CA9 expression may show hypoxia levels of clinical importance.\nEXPERIMENTAL DESIGN: We assessed the expression of CA9 and the microvessel density (MVD; CD31-positive) in 75 locally advanced squamous cell head and neck cancers treated with concurrent chemoradiotherapy with carboplatin.\nRESULTS: Strong membrane/cytoplasmic CA9 expression, noted in 20/75 (26.6%) tumors, mainly occurred in tumors with very poor vascularization (expression in 63% versus 14%; P \u003c 0.0001), was located around areas of focal necrosis, and was related to poor complete response rate (40% versus 70%; P = 0.02). These observations suggested that CA9 might be a marker of clinically important hypoxia. Combining the CA9 staining and the tumor angiogenicity (MVD), we identified three groups of patients: (a) hypoxic tumors; (b) euoxic highly angiogenic tumors; and (c) euoxic non-highly angiogenic tumors. Groups (a) and (b) had a very poor local relapse-free survival (P \u003c 0.0001).\nCONCLUSIONS: Stratification of patients undergoing radical radiotherapy using the CA9/MVD model may be useful for the individualization of therapeutic strategies combining antiangiogenesis and hypoxia targeting with radiotherapy."}